Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavacamten vs cibenzoline on exercise tolerance in obstructive hypertrophic cardiomyopathy
jRCT1041260015Recruiting
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of mavacamten in hypertrophic cardiomyopathy (HCM). Primary endpoint: Primary: Change in peak VO2 after switching to mavacamten. Started Jun 2026; status: recruiting.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on jRCT1041260015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041260015.